with adcetris we did a partnership with takeda and we own u.s.nd canada and we have sales reps selling the product and we approved it now in over 35 countries, the millennium group from takeda sells it internationally and we get milestone payments and royalties. >> sg75, phase one clinical trial of renal cell carcinoma. when i see phase one, it basically means three years before you see any results on this? >> sometimes it's quicker than that. we have seven products that we are developing in clinical trials and the first was for aml, acute myeloma leukemia. we have a new one that just started in phase one that we've been working on for years, jim. >> one of the things, some of the analysts -- a lot of people feel that literally that the cycle, that everything's gotten overheated, and i get that, but regeneron and celgene, you guys have been delivering, and i didn't really understand this, frankly. included in the quarterly update we heard was that the fda will not consider label expansion for adcetres to include a retreatment claim at this time.